chlorambucil has been researched along with s 1033 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aloyz, R; Amrein, L; Davidson, D; Miller, WH; Panasci, L; Petruccelli, LA; Shawi, M | 1 |
1 review(s) available for chlorambucil and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for chlorambucil and s 1033
| Article | Year |
|---|---|
Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.
Topics: Antineoplastic Agents, Alkylating; B-Lymphocytes; Benzamides; Blotting, Western; Chlorambucil; Comet Assay; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombination, Genetic; Tumor Cells, Cultured | 2011 |